Items tagged with Drug-resistant TB

Urgent action necessary for equitable access to bedaquiline in all countries with high burdens of TB, MDR-TB, and TB/HIV (post with simple image)

Advocates demand that Johnson & Johnson commit to non-enforcement of secondary patent on bedaquiline so that access to generic, quality-assured bedaquiline is guaranteed after the primary patent expires on 18 July 2023.

Global Drug Facility update on access to bedaquiline (post with simple image)

Global Drug Facility announces an agreement with Johnson & Johnson for access to affordable generic versions of bedaquiline; Treatment Action Group, Médecins Sans Frontières and Partners in Health release statements in response to the agreement.

Open letter to Johnson & Johnson requesting clarification on the recent deal on generic bedaquiline supply (post with simple image)

Advocates call for clarity on the terms of the Johnson & Johnson's deal with the Stop TB Partnership’s Global Drug Facility to supply generic bedaquiline.

Global Drug Facility announces price reductions up to 55% for bedaquiline (post with simple image)

The new prices are valid through December 2024 and present price reductions up to 55% compared to the previous price of US$289 for a 6-month treatment course of bedaquiline.

Open letters to Johnson & Johnson requesting equitable access to bedaquiline (post with simple image)

Ukraine, Belarus, Azerbaijan and Moldova demand that Johnson & Johnson take urgent action to improve equitable access to bedaquiline in all countries with a high burden of TB.

Johnson & Johnson confirms intent not to enforce patents for SIRTURO® (bedaquiline) for the treatment of multidrug-resistant TB in 134 low- and middle-income countries (post with simple image)

The decision is intended to assure current and future generic manufacturers that they may manufacture and sell generic versions of SIRTURO® without a concern that the Company will enforce its bedaquiline patents, provided the generic versions of SIRTURO® are of good quality, medically acceptable, and are used only in the 134 low- and middle-income countries.

Johnson & Johnson pricing agreement for critical TB drug still unfairly restricts access in countries where the need is greatest (post with simple image)

Unitaid calls on Johnson & Johnson to drop secondary patents for the drug-resistant TB medicine bedaquiline, and to make negotiated rates with the Stop TB Partnership’s Global Drug Facility available to all countries, regardless of how they purchase drugs.

An Activist’s Guide to Shorter Treatment for Drug-Resistant TB (post with simple image)

This new resource lays out what activists need to know about the new drug-resistant TB treatment regimens, and equips them with actions they can take and arguments they can use to advocate for access to those regimens.

Landmark clinical trial redefines multidrug-resistant TB treatment options (post with simple image)

endTB clinical trial offers multiple new shortened drug regimens to treat adults and children with multidrug–resistant TB.

High cure rate with drug-resistant TB regimen (post with simple image)

Results of LIFT-TB operational research on BPaL regimen for treating drug-resistant TB in Central and Southeast Asia.

Page 112 of 113 · Total posts: 0

←First 111 112 113 Last→